Literature DB >> 11690701

Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.

C Loguercio1, V De Girolamo, I de Sio, C Tuccillo, A Ascione, F Baldi, G Budillon, L Cimino, A Di Carlo, M P Di Marino, F Morisco, F Picciotto, L Terracciano, R Vecchione, V Verde, C Del Vecchio Blanco.   

Abstract

BACKGROUND/AIMS: Studies on non-alcoholic fatty liver disease (NAFLD) have included chronic liver damage attributed to various causes. Our investigation was held to observe the main clinical, histological, and pathophysiological aspects of NAFLD in patients not exposed to any known cause of chronic liver disease.
METHODS: We evaluated, in 84 in-patients (male/female, 66/18; median age, 36 years), the clinical and biochemical characteristics of NAFLD, and particularly its association with diabetes, dyslipidemia, hyperinsulinemia and/or with the increase of parameters of oxidative stress (blood levels of malonyldialdehyde, 4-hydroxynonenal and total plasma antioxidant capacity).
RESULTS: Ninety percent of patients had an increased body mass index (BMI), 35% had dyslipidemia, 40% had sub-clinical diabetes (only 3% had overt diabetes), 60% had hyperinsulinemia, and more than 90% had enhanced levels of lipid peroxidation markers. In 48 patients who had consented to liver biopsy, we found: 14 with simple steatosis, 32 with steatohepatitis, and two with cirrhosis.
CONCLUSIONS: Our data indicate that in our country, NAFLD may occur in young males with an increased BMI, with or without hyperinsulinemia, dyslipidemia and diabetes, generally associated with disorders of redox status, and that it may be differentiated from steatosis to steatohepatitis or cirrhosis only with a liver biopsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11690701     DOI: 10.1016/s0168-8278(01)00192-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  42 in total

1.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey.

Authors:  Lei Shen; Jian-Gao Fan; Yan Shao; Min-De Zeng; Jun-Rong Wang; Guo-Hao Luo; Ji-Qiang Li; Si-Yao Chen
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

2.  Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women.

Authors:  Seong-Su Moon; Young-Sil Lee; Sung Woo Kim
Journal:  Endocrine       Date:  2012-03-11       Impact factor: 3.633

3.  Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.

Authors:  Paola Loria; Amedeo Lonardo; Francesca Leonardi; Cristina Fontana; Lucia Carulli; Anna Maria Verrone; Andrea Borsatti; Marco Bertolotti; Fabio Cassani; Alberto Bagni; Paolo Muratori; Dorval Ganazzi; Francesco B Bianchi; Nicola Carulli
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

4.  Protective effect of andrographolide against concanavalin A-induced liver injury.

Authors:  Guojun Shi; Zhijian Zhang; Rong Zhang; Xiaofang Zhang; Yan Lu; Jian Yang; Di Zhang; Zhiguo Zhang; Xiaoying Li; Guang Ning
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

Review 5.  Lytic cell death in metabolic liver disease.

Authors:  Jérémie Gautheron; Gregory J Gores; Cecília M P Rodrigues
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

6.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 7.  Managing nonalcoholic fatty liver disease: recommendations for family physicians.

Authors:  Ignazio Grattagliano; Piero Portincasa; Vincenzo O Palmieri; Giuseppe Palasciano
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

Review 8.  Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis.

Authors:  Shivakumar Chitturi; Jacob George
Journal:  Curr Gastroenterol Rep       Date:  2003-02

9.  Curcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reduction.

Authors:  Long Wang; Yisong Lv; Huixiang Yao; Li Yin; Jianhui Shang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys.

Authors:  Hyeon Chang Kim; Kui Son Choi; Young Hwa Jang; Hae Won Shin; Dae Jung Kim
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.